Green Thumb Industries Inc. (GTBIF) Stock Price & How to Invest

Last updated November 2026

Short answer

Green Thumb Industries (GTBIF) is one of the largest and most consistently profitable US multi-state cannabis operators, with ~$1.24B in trailing revenue across 14 markets. At ~$5.69 and a ~$1.25B market cap (November 20, 2026), it trades near 1.0x sales, a low multiple that reflects federal illegality, price compression and OTC-only US trading, not weak operations. The stock is down about 30% in 2026 even though third-quarter revenue grew ~11% and same-store sales turned positive, because that quarter also brought a small GAAP net loss and margin pressure. Rescheduling and new adult-use states are the swing factors.

GTBIF stock price

As of 2026-11-20, Green Thumb Industries Inc. (GTBIF) last closed at $5.51, down 5.8% over the past year. Over the past 52 weeks it has traded between $5.51 and $9.69.

GTBIF last close
$5.51
1 day
-5.65%
1 month
-16.26%
1 year
-5.81%
52-week range
$5.51 to $9.69
Last close
2026-11-20

Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Green Thumb Industries Inc.'s investor relations page. Walnut is informational, not investment advice.

GTBIF key stats

At $5.51 on November 20, 2026, Green Thumb Industries Inc. (GTBIF) has a market cap of $1.2B and a P/E of 13.1 on trailing earnings (21.2 on forward earnings).

Market cap
$1.2B
P/E (trailing)
13.1
P/E (forward)
21.2
EPS (trailing 12 months)
$0.42
Price to book
0.6
Beta
1.14

Market cap, P/E and yield are measured at the $5.51 price on November 20, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.

What's new with Green Thumb Industries Inc. (GTBIF)?

The last two weeks for Green Thumb Industries Inc., as of November 22, 2026: the price move, the next earnings date, and what analysts changed.

  • GTBIF closed at $5.51 on November 20, 2026, down 10.0% over the past five trading days (from $6.12).

Prices are daily closes from Yahoo Finance. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.

What does Green Thumb Industries Inc. (GTBIF) do?

Green Thumb Industries is a Chicago-based cannabis company founded in 2014 by Ben Kovler. It grows, processes and sells cannabis under consumer brands such as Rythm (flower and vapes), Dogwalkers (pre-rolls), incredibles (edibles) and Beboe, and it runs roughly 100 to 115 RISE and other branded dispensaries across 14 US markets, including Illinois, Pennsylvania, Florida, New Jersey, Ohio, Minnesota, Connecticut and Nevada. Because cannabis remains federally illegal for adult use, its shares cannot list on a US exchange: they trade over the counter as GTBIF and on the Canadian Securities Exchange as GTII.

The business has been steady, not fast-growing. Full-year 2025 revenue was ~$1.18B, up ~3.4%, with GAAP net income of ~$114M (helped by warrant fair-value gains) and ~$295M of operating cash flow. In Q2 2026, revenue rose ~4.6% to ~$306.7M and GAAP net income was only ~$4.9M. Q3 2026, reported November 4, was a step up on the top line: revenue rose ~11% to ~$324.4M, driven by Minnesota adult-use retail and existing markets, and comparable-store sales grew ~3%, the first positive comp since Q3 2024. Normalized EBITDA was ~$89M (~28% of revenue) and operating cash flow ~$58M. Gross margin held near ~45%, down from ~49% a year earlier, with ~$15.8M of brand licensing fees a major factor, and SG&A rose to ~$122M. The company posted a GAAP net loss of ~$4.8M, ending its run of profitable quarters, while adjusted EPS of ~$0.07 beat the ~$0.04 consensus. Cash rose to ~$316M. Management guided fourth-quarter revenue flat to slightly down sequentially and expects further margin compression.

The investment picture is a contest between solid fundamentals and a hostile structure. In April 2026, the Justice Department moved state-licensed medical marijuana into Schedule III, which ended the punitive Section 280E tax on parts of Green Thumb's business and cut its Q2 tax bill to ~$12.5M from ~$21.6M. Adult-use cannabis still sits in Schedule I, so most of the revenue base still faces 280E and banking limits, and management warned on the Q3 call that delays in broader rescheduling mean continued significant tax liabilities. Bulls point to a ~13.5x trailing earnings multiple, EV/EBITDA under 6x, a large cash balance, Florida store openings and upside from broader rescheduling or new states such as Virginia and Texas. Skeptics point to years of falling prices, a forward P/E near 22x on lower expected earnings, and the risk that policy relief stays partial. As of November 20, 2026 the shares closed at ~$5.69, down ~30% year to date but up ~8% over a year.

What's driving Green Thumb Industries Inc. (GTBIF)?

1. Federal rescheduling and the end of 280E

The single largest driver is federal policy. The April 2026 order placed state-licensed medical marijuana in Schedule III, and Green Thumb says Section 280E stopped applying to those operations from April 28, 2026. That was visible right away: Q2 income tax expense fell to ~$12.5M from ~$21.6M. Adult-use sales, which are most of the company's revenue, still fall under Schedule I, and a broader administrative hearing ran from late June into July 2026 without a final decision by the Q3 call in November. If adult-use cannabis is also moved to Schedule III, Green Thumb would stop paying tax on gross profit and pay it on net income, which could add tens of millions of dollars a year to free cash flow and could narrow the discount to ordinary consumer companies. Management has said it is not interested in uplisting or restructuring the business until scheduling and tax clarity improve.

2. New adult-use markets and store openings in its footprint

Green Thumb's growth has come in steps each time a state it already serves converts from medical to adult-use. Minnesota is the current example: its eight RISE dispensaries switched to adult-use in September 2025 and drove much of the ~11% Q3 2026 revenue growth, though management now expects that market to lean more toward wholesale as competing stores open. The company plans 3-5 new Florida stores before year-end 2026 and 10 or more in 2027, plus 1-2 in Ohio. Virginia adult-use sales are scheduled to begin July 1, 2027, where the company has invested heavily, and in Texas it holds a conditional license under the Compassionate Use Program and recently bought a facility outside Fort Worth, though timing there is uncertain. Pennsylvania and Florida remain medical-only and are the largest potential prizes.

3. Brand strength and wholesale share

Unlike many operators that rely mostly on their own stores, Green Thumb sells heavily through third-party dispensaries. On the Q3 2026 call management said Rythm ranked first nationally in branded flower and Dogwalkers first in uninfused pre-rolls, and incredibles is a leading edibles name in several states. Brand pull matters because flower prices keep falling: the company's gross margin slid from ~52.9% in 2024 to ~48.9% in 2025 and ~45% in Q2 and Q3 2026. A strong brand portfolio gives some pricing support and shelf space when competitors discount. It also positions the company for a future in which interstate commerce is permitted, since national brands would travel more easily than local ones.

4. Capital returns and balance sheet strength

Green Thumb is one of the few cannabis companies that generates enough cash to return it. Operating cash flow was ~$295M in 2025 and ~$253M over the trailing twelve months to September 2026. The board expanded its buyback to a $150M maximum in April 2026, and in the first half of 2026 the company repurchased ~13.4M shares at an average of ~$5.78, bringing cumulative buybacks to ~29.5M shares for ~$203M. Cash rose to ~$316M at September 30, 2026. Yahoo Finance reports total debt of ~$554.5M, a figure that can include lease liabilities, so the balance sheet is less net-cash than the ~$283M of debt the company cited at June 30 suggests. Management describes itself as cautious on M&A, which leaves room for store openings and buybacks without diluting shareholders.

What are the risks to Green Thumb Industries Inc. (GTBIF)?

The main risk is regulatory. Adult-use cannabis remains a Schedule I substance, so most of Green Thumb's sales still face Section 280E, restricted banking and no access to US stock exchanges. A broader rescheduling decision could be delayed, narrowed or challenged in court, the IRS has not issued complete guidance on how the April 2026 order applies, and management has warned that delays mean continued significant tax liabilities. Price compression is the second risk: gross margin fell roughly eight points in two years to ~45% in Q3 2026, management expects further compression in coming quarters, and new cultivation capacity in states like Illinois, New Jersey and Ohio continues to push prices down. Third, intoxicating hemp-derived THC products, now sold in mainstream retailers, compete for the same customers without cannabis licensing costs or taxes, although management said changes in hemp policy could become a tailwind. Fourth, profitability is lumpy: 2025 GAAP net income leaned on warrant fair-value gains, Q2 2026 GAAP net income was only ~$4.9M, and Q3 2026 was a GAAP net loss of ~$4.8M as SG&A rose. Consensus expects 2026 EPS of only ~$0.11 before a rebound to ~$0.36 in 2027, so the forward multiple depends on that recovery. Finally, GTBIF trades OTC with lower liquidity and higher volatility than listed stocks, many US brokers restrict cannabis names, analyst coverage on Yahoo Finance is thin (two analysts), and founder voting control limits outside shareholder influence. Growth also depends on a short list of state catalysts: Virginia adult-use is not scheduled until mid-2027, Texas timing is uncertain, and Pennsylvania and Florida have repeatedly stalled on adult-use legalization.

Is GTBIF a buy or a sell?

We give no verdict on Green Thumb Industries Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Federal rescheduling and the end of 280E. The single largest driver is federal policy.

The case against. The main risk is regulatory.

Read the full bull and bear case on GTBIF, including what would have to change to break either one. Walnut is not an investment adviser.

How is Green Thumb Industries Inc. (GTBIF) valued?

Market cap, P/E and dividend yield at today's price are in the GTBIF key stats above. The business figures below come from Green Thumb Industries Inc.'s reported results as of November 2026 and change when it next reports.

  • Revenue (TTM): ~$1.24B; Q3 2026 ~$324.4M, up ~11%
  • Net income (TTM): ~$98.7M (~7.9% margin); Q3 2026 GAAP loss ~$4.8M
  • Q3 2026 adjusted EPS: ~$0.07 vs ~$0.04 expected
  • Q3 2026 gross margin: ~45% (vs ~49% a year earlier)
  • Cash / total debt: ~$316M / ~$554.5M (Yahoo, Sept 30, 2026)

As of November 2026: At ~$5.69, Green Thumb is valued at roughly 1.0 times trailing sales and about 13.5 times trailing earnings, with enterprise value under six times trailing EBITDA. The forward P/E is higher, near 22x, because consensus expects 2026 EPS of only ~$0.11 before ~$0.36 in 2027. Those multiples are low for a company with ~28% normalized EBITDA margins and positive cash flow, and the gap reflects federal illegality, 280E taxes, OTC-only trading in the US and steady price compression. The next data points are a federal rescheduling decision and the Q4 2026 report, where management has guided revenue flat to slightly down sequentially (consensus ~$323.5M).

Who competes with Green Thumb Industries Inc. (GTBIF)?

US multi-state operators

Curaleaf, Trulieve, Verano Holdings and Cresco Labs compete with Green Thumb for retail licenses, wholesale shelf space and investor capital. Trulieve dominates Florida, where Green Thumb is now adding stores, Verano and Cresco overlap heavily in Illinois, Pennsylvania and New Jersey, and Curaleaf has the broadest footprint. Green Thumb tends to stand out on profitability and balance sheet strength more than on scale.

Canadian licensed producers

Tilray Brands, Canopy Growth and SNDL list on US exchanges because their cannabis operations sit in Canada and other federally legal markets. They compete for the same thematic investor dollars and would be positioned to enter US cannabis if federal law changed, but they have generally reported weaker margins than leading US operators.

Hemp-derived THC and alternatives

Intoxicating hemp products, including THC beverages and delta-8 gummies now carried by large retailers in several states, compete directly with licensed cannabis on price and convenience without the same taxes or licensing costs. Alcohol and beverage companies experimenting with THC drinks add another source of pressure on Green Thumb's edibles and beverage lines.

What stocks are similar to Green Thumb Industries Inc. (GTBIF)?

Other names that sit close to GTBIF: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.

How to invest in Green Thumb Industries Inc. (GTBIF)

There are three common ways to get GTBIF exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so GTBIF sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where GTBIF fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

The bottom line on Green Thumb Industries Inc. (GTBIF)

GTBIF is a cash-generative cannabis leader priced like a distressed one, at about 1x sales and 13.5x trailing earnings after a ~30% fall in 2026. Q3 2026 showed the operating business growing again (revenue +11%, comparable sales +3%) while gross margin and GAAP profit kept slipping. Whether the discount closes depends far more on federal policy and state price trends than on Green Thumb's own execution.

More on Green Thumb Industries Inc. (GTBIF)

Whether GTBIF is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is GTBIF a buy or a sell?, and where the stock could go from here in the GTBIF stock forecast.

For income investors, whether GTBIF pays a dividend and how the payout looks is covered in does GTBIF pay a dividend? And to weigh GTBIF against a peer, read the full side-by-side comparisons: GTBIF vs NJR and GTBIF vs TLRY.

Wondering how GTBIF fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Green Thumb Industries Inc.

Ask Walnut's AI anything about GTBIF and see how it fits what you own.

FAQ

What does Green Thumb Industries do?

+

Green Thumb Industries is a vertically integrated US cannabis company. It cultivates and processes cannabis in licensed facilities, makes branded products such as Rythm flower and vapes, Dogwalkers pre-rolls, incredibles edibles and Beboe, and sells them both through its own dispensaries (mostly under the RISE name) and wholesale to other licensed stores. It operates in 14 US markets, including Illinois, Pennsylvania, Florida, New Jersey, Ohio, Minnesota, Connecticut, Massachusetts, Maryland, Nevada and New York, with roughly 100 to 115 stores. The company is headquartered in Chicago, was founded in 2014 by CEO Ben Kovler, and generated ~$1.24B of revenue over the trailing twelve months to September 2026.

Why does GTBIF trade over the counter instead of on the NYSE or Nasdaq?

+

US stock exchanges will not list companies that touch cannabis that remains illegal under federal law, and adult-use cannabis is still a Schedule I substance. Green Thumb therefore lists on the Canadian Securities Exchange as GTII and trades in the US on the OTC market as GTBIF. That has practical effects: lower liquidity, wider bid-ask spreads, exclusion from major indexes and many institutional mandates, and the fact that some US brokerages and custodians restrict buying cannabis stocks altogether. Many observers attribute part of the sector's low valuation to this structure. A federal change that allowed uplisting to a major US exchange would likely broaden the shareholder base, though timing is uncertain, and management said in November 2026 it is not pursuing an uplisting until federal scheduling and tax treatment are clearer.

How did Green Thumb perform in its most recent quarter?

+

In Q3 2026, reported November 4, revenue rose ~11% year over year to ~$324.4M, led by Minnesota adult-use retail, and comparable-store sales grew ~3%, the first positive comp since Q3 2024. Gross margin was ~45%, down from ~49%, and SG&A rose to ~$122M. The company posted a GAAP net loss of ~$4.8M, but adjusted EPS of ~$0.07 beat the ~$0.04 consensus and normalized EBITDA was ~$89M, about 28% of revenue. Cash ended at ~$316M. Management guided Q4 revenue flat to slightly down and expects more margin compression.

What does rescheduling mean for Green Thumb?

+

In April 2026, the Justice Department moved FDA-approved marijuana products and marijuana sold under a qualifying state medical license into Schedule III. For Green Thumb, the key effect is tax: Section 280E, which bars deductions for businesses trafficking Schedule I or II substances, stopped applying to its medical operations from April 28, 2026, and Q2 income tax expense fell to ~$12.5M from ~$21.6M. Adult-use cannabis, which makes up most of its revenue, remains in Schedule I and still faces 280E. A broader rescheduling proceeding was still pending as of the November 2026 earnings call. Full Schedule III treatment would not legalize interstate commerce or exchange listings by itself, but it would materially raise after-tax cash flow.

Is Green Thumb profitable?

+

Mostly, by cannabis-industry standards, though Q3 2026 was a small GAAP loss. It reported GAAP net income of ~$114.2M for 2025, although a meaningful part came from favorable fair-value adjustments on related-party warrants; income from operations was ~$137.7M versus ~$224.4M in 2024. Normalized EBITDA was ~$348M in 2025, about 29.6% of revenue, and operating cash flow was ~$295M. Profit has been squeezed by price compression and 280E taxes: Q2 2026 GAAP net income was ~$4.9M and Q3 2026 a ~$4.8M loss, despite normalized EBITDA of ~$84M and ~$89M. Trailing net income is ~$98.7M, a P/E of roughly 13.5x.

Does Green Thumb pay a dividend or buy back shares?

+

Green Thumb does not pay a regular dividend. Its capital return has come through share repurchases. The board expanded the buyback program in April 2026 to a maximum of $150M, and in the first six months of 2026 the company repurchased ~13.4M subordinate voting shares at an average price of ~$5.78. Cumulatively, it has repurchased ~29.5M shares for ~$203.4M, with ~$62.3M of authority remaining as of the Q2 2026 report, available through September 2026. Whether that authority is renewed or expanded is something to watch in later filings. Buybacks reduce share count, which supports per-share earnings even when total revenue grows slowly.

Who are Green Thumb's main competitors?

+

Among US multi-state operators, the closest peers are Curaleaf, Trulieve, Verano Holdings and Cresco Labs. They compete for licenses, retail locations and wholesale shelf space, with heavy overlap in Illinois, Pennsylvania, New Jersey, Ohio and Florida. Canadian licensed producers such as Tilray Brands, Canopy Growth and SNDL compete more for investor capital than for US customers today. A growing competitive threat comes from hemp-derived THC products, including drinks and gummies sold in mainstream stores, which can undercut licensed cannabis on price because they avoid state cannabis taxes and licensing costs. Green Thumb's differentiators are its brand portfolio, its relatively strong margins and its cash balance of ~$316M.

How has GTBIF stock performed in 2026?

+

As of November 20, 2026, GTBIF closed at about $5.69, down roughly 30% year to date, about 24% over three months and 10% over the past month, though up about 8% over the past year. Its 52-week range is about $5.29 to $10.43. The slide continued after the Q3 2026 report, which paired 11% revenue growth with a GAAP net loss and a warning of further margin compression.

What are the biggest risks of owning GTBIF?

+

The main risks are regulatory and pricing. Federal policy could stall, leaving adult-use sales under Schedule I with 280E taxes and limited banking. Falling wholesale and retail prices have already cut gross margin from ~52.9% in 2024 to ~45% in Q3 2026, and management expects more compression. Hemp-derived THC products are taking share in some states. The stock trades OTC with lower liquidity, some brokers restrict it, and price swings around policy headlines can be large: it was down about 30% year to date by November 20, 2026. Founder voting control also limits outside influence. Walnut is not an investment adviser; these points describe the risks and do not suggest any action.

Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Green Thumb Industries Inc.'s investor relations page or your broker before making investment decisions.